Please enable Javascript
Knowledge Hubs
The latest news on genitourinary oncological disease states.
Prostate Cancer Knowledge Hubs
Prostate Cancer
Localized
mCSPC
CRPC
RLT
Prostate Cancer Diagnostics
Prostate Cancer
Localized
mCSPC
CRPC
Advertisement
Renal Cell Carcinoma Knowledge Hubs
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Renal Cell Carcinoma Diagnostics
Renal Cell Carcinoma
Localized Renal Cell Carcinoma
Advanced Renal Cell Carcinoma
nccRCC
Advertisement
Urothelial Carcinoma Knowledge Hubs
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Urothelial Carcinoma Diagnostics
Urothelial Carcinoma
Non-Muscle Invasive Urothelial Carcinoma
Muscle Invasive Urothelial Carcinoma
Advanced Urothelial Carcinoma
Testicular, Penile, and Rare Malignancies Knowledge Hubs
Testicular, Penile, and Rare Malignancies
Testicular, Penile, and Rare Malignancies
Roundtable Discussions
Discussing New Game-Changing Studies in Prostate Cancer
Tanya Dorff, MD
CRPC
|
October 15, 2024
In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024.
Decision-Making When Considering ADT and Doublet or Triplet Therapy for CRPC
Tanya Dorff, MD
CRPC
|
October 15, 2024
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
PSMA/PET Scans and ADT in Patients With CRPC
Tanya Dorff, MD
CRPC
|
October 15, 2024
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
Nephrectomy Versus Systemic Therapy and Risk Stratification in Papillary, Non-Papillary nccRCC
Daniel Joyce, MD
nccRCC
|
October 15, 2024
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
IO/TKI and PD-L1 Approaches, Trials in nccRCC
Daniel Joyce, MD
nccRCC
|
October 15, 2024
In part 2, new trials in the nccRCC treatment landscape are reviewed, and the use of IO/TKI and PD-L1 are discussed.
Management of Papillary Metastatic nccRCC
Daniel Joyce, MD
nccRCC
|
October 15, 2024
In the first segment of this roundtable series, the panelists discuss the management of papillary metastatic nccRCC.
View Full Archive
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCO
Editor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MD
Editor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPH
Editor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, PhD
Editor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MD
Editor | Urologist at Swedish Health Services
David Ambinder, MD
Editor | Urology Resident at New York Medical College/Westchester Medical Center